Role of Lactobacillus in cervical cancer

Abstract: Cervical cancer is a common malignant cancer among women worldwide. Changes in the vaginal microecological environment lead to multiple gynecological diseases, including cervical cancer. Recent research has shown that Lactobacillus may play an important role in the occurrence and development of cervical cancer. This review explores the role of Lactobacillus in cervical cancer. A total of 29 articles were included after identification and screening. The pertinent literature on Lactobacillus in cervical cancer from two perspectives, including clinical studies and experimental studies, was analyzed. An association network for the mechanism by which Lactobacillus induces cervical cancer was constructed. In addition, we provide direction and insight for further research on the role of Lactobacillus in cervical cancer.

Keywords: CIN, cervical cancer, Lactobacillus, microorganism

Introduction

Cervical cancer is the third most commonly diagnosed cancer and the fourth leading cause of cancer-related deaths among women worldwide.1,2 Epidemiological investigations have shown that the number of new cases of cervical cancer per year is ~485,000, with 236,000 deaths occurring per year globally.3 Patients with cervical cancer often exhibit no obvious symptoms and signs at early stages; thus, the disease tends to be ignored and is easily misdiagnosed. Cervical cytologic screening has generally been used to detect cervical cancer and premalignant lesions over the past decade, and early diagnosis and appropriate treatment reduce the risk of cancer-related death.4

Current research has shown that microorganisms may play an important role in the occurrence and development of cervical cancer.5 Persistent infection with high-risk human papillomavirus (HR-HPV) is now believed to be a major causal factor in the development of the disease.6 The bacteria in the vagina maintain a dynamic balance under physiological conditions, but the imbalance of vaginal flora leads to multiple gynecological diseases, such as coleitis, high-grade cervical intraepithelial neoplasia (CIN), and cervical cancer.7 It has been confirmed that Gardnerella and Monilia are the main bacteria that induce coleitis.8,9 Previous research has shown that the abundance of vaginal flora such as Mycoplasma genitalium,10 aerobic lactobacilli, Staphylococcus epidermidis, Enterococci, Escherichia coli, and Bacteriodes species11 in patients with cervical cancer is different from that in healthy controls. However, the relationship between vaginal flora and cervical cancer has not yet been elucidated.

Lactobacillus is a group of bacteria that can act as a catalyst to produce lactic acid during the process of glycolysis.12 This group is the predominant bacteria in the healthy vagina and plays an important role in the protection of the female reproduction...
system. Summarizing previous studies, Lactobacillus in the vagina exerts its protective functions mainly through the following four potential mechanisms: 1) By preventing pathogenic bacteria from adhering to the epithelial tissue: vaginal epithelial cells (VECs) of fertile woman encounter periodic changes including hyperplasia, peeling, and repair under the effect of estrogen and progesteron. Free glycogen that is produced during this process supplies matter and energy for the growth of Lactobacillus. Lactobacillus is adsorbed and occupies the VECs, and these bacteria can prevent the conglutination of invasive pathogenic bacteria that induce malignant tumors. 2) By secreting organic acid: Lactobacillus produces organic acid by decomposing glucogen to maintain the vaginal acidic environment, which can inhibit the growth and resist the invasion of pathogenic bacteria. In addition, the vaginal acidic environment is beneficial to maintain the activity of bacteriocins and H$_2$O$_2$. 3) By secreting various metabolites: exopolysaccharides (EPSs), phosphorylated polysaccharides, and peptidoglycans, which are secreted by Lactobacillus, can inhibit the proliferation of malignant tumors. Bacteriocin and surface-active components can inhibit the production of tumorigenic substances and the growth of harmful microorganisms. H$_2$O$_2$, which is also secreted by Lactobacillus, can directly kill harmful microorganisms or act in a bactericidal manner though the peroxidase-hydrogen peroxide-halide bactericidal system. 4) By activating the immune system: Lactobacillus affects cellular and humoral immunity. On one hand, these bacteria can increase the proliferation and differentiation of thymus-derived cells (T cells). On the other hand, Lactobacillus, as an immune sensitiser, can increase immunological recognition and proliferation of bone marrow-derived cell (B cells). Lactobacillus also produces nitric oxide (NO) by stimulating macrophages and disrupting the energy metabolism of cancer cells. Considering the importance of lactobacilli in cervical cancer, in this review, we comprehensively analyzed and classified the pertinent literature on lactobacilli in cervical cancer from two perspectives, clinical case investigations, and studies of molecular mechanisms. We also provide direction and insight for further research on intestinal flora in cervical cancer.

**Methods**

The databases PubMed, Embase, and Cochrane were searched for literature published up to January 10, 2018. To achieve maximum sensitivity of the search strategy and identify all studies, the following terms were combined: (“cervix uterus” or “neck of uterus” or “uterine neck” or “cervical” or “cervix” or “uterine cervical” or “uterine cervix”) and (“neoplasms” or “tumor” or “carcinoma” or “cancer” or “intraepithelial neoplasia” or “intraepithelial neoplasms”) and (“lactic acid bacteria” or “lactobacillus” or “lactobacilli” or “vagina/vaginal flora” or “vagina/vaginal microflora” or “vagina/vaginal microorganism” or “vagina/vaginal microbiome” or “vagina/vaginal microbe” or “vagina/vaginal microbiology” or “vagina/vaginal bacteria” or “vagina/vaginal bacterium”). All relevant abstracts were independently retrieved by two authors, and the articles with available information for the present systematic review were fully reviewed. A total of 29 articles were included after identification and screening. The detailed search strategy is presented in Figure 1.

**Study selection**

Studies adhering to the following criteria were considered for inclusion: 1) those published in English and 2) those involving Lactobacillus in CIN or cervical cancer in vivo or in vitro. The exclusion criteria were as follows: 1) letters, case reports, reviews, or conference reports; 2) the main studies not focused on the topic of vaginal Lactobacillus in CIN or cervical cancer; and 3) correlation clinical studies with a low quality score according to the Grading of Recommendations, Assessment, Development and Evaluation (GRADE) method.

**Results**

CIN, which is considered to be a precancerous lesion of the cervix, was included in the present study. After identification, screening, and validation, we identified a total of 29 pertinent studies related to Lactobacillus and several of its subgenera in cervical cancer and precancerous lesions of the cervix published in recent years. The 29 pertinent studies were divided into two groups that comprised 14 clinical studies in one group and 15 experimental studies in the other group. The clinical studies and experimental studies are shown in Tables 1 and 2, respectively.

As shown in Table 1, 16S rRNA gene sequencing was the main method used to detect microbial community structure and relative abundance. The presence of cervical cancer and precancerous lesions in women was associated with a high relative abundance of Lactobacillus iners and Lactobacillus sp and low relative abundance of Lactobacillus jensenii and Lactobacillus crispatus. Two investigations revealed that the abundance of Lactobacillus in women with human papillomavirus (HPV) infection was lower (panel numbers 6 and 10). A randomized, double-blind, placebo-controlled study...
showed that an oral lactobacilli (panel number 11) and an HR-HPV E7-expressing *Lactobacillus*-based vaccine (panel number 8) were able to decrease the risk of CIN. Moreover, two randomized controlled trial studies (panel numbers 12 and 13) supported the hypothesis that LC9018 (a biological response modifier prepared from heat-killed *Lactobacillus casei* YTT9018) was able to protect patients from radiation-induced leukopenia with few side effects.

As shown in Table 2, cancer cell and animal models were used along with molecular biology techniques such as the cell counting kit-8 assay, Western blots, immunohistochemistry, polymerase chain reaction, and enzyme-linked immunosorbent assays to study the role of *Lactobacillus* and several subgenera in cervical cancer. The results showed that *Lactobacillus*, its subgenera, and their supernatants exhibited antimetastatic and antiproliferative activities in cervical cancer cell lines by regulating cancer-related genes and eliciting an immunological response. *Lactobacillus* inhibited the viability of cervical cancer cells through regulating HPV oncogenes (panel numbers 1 and 6), and HPV-type 16 E7 protein displayed on lactobacillus could protect against HPV-induced tumors through regulating cellular immunity (panel numbers 10–14). In particular, a negative result showed that *L. casei* extract was not able to inhibit the viability of cervical cancer cells in vitro (panel number 7).

As shown in Figure 2, a network of the mechanisms of *Lactobacillus* in cervical cancer was constructed to better visualize the theory behind the experimental studies.

**Discussion**

The vaginal microecological balance is dynamic and relative, and patients are able to recover from slight vaginal dysbacteriosis. The persistence of vaginal dysbacteriosis is thought to promote gynecological cancer.7,27 A decline in the quantity and activity of *Lactobacillus* leads to an overgrowth of anaerobic bacteria.28 Deleterious metabolites such as nitrous acid can be produced by these organisms, and the risk of HPV infection also increases.29 Persistent infection of oncogenic HPV is a cause of cervical cancer.6 The abundance of *Lactobacillus* in HPV infection is lower, and HPV oncogenes may be involved in regulation of the viability of cervical cancer cells inhibited by *Lactobacillus*. CIN, precancerous lesions of the cervix, is much more likely to occur with dysbacteriosis. Thus, the regulation and control of *Lactobacillus* may block the progression of cervical cancer.

The present study attempts to clarify the cross-talk between *Lactobacillus* and cervical cancer using both clinical and experimental studies by reviewing the pertinent literature. Experimental study can lay an important foundation for...
Table 1 Clinical studies of Lactobacillus in cervical cancer

| Number | Year | Authors | Number of women enrolled | Race or region | Subgenera of Lactobacillus | Methods | Diseases | Findings | Reference |
|--------|------|---------|--------------------------|----------------|---------------------------|---------|----------|----------|-----------|
| 1      | 2016 | Piyathilake et al | Patients with CIN1 (n=90), CIN2 (n=208), and CIN3 (n=132) | Birmingham, AL, USA | Lactobacillus reuteri and several sub-genus level | 16S rRNA sequencing | CIN | The cervical mucosal CT dominated by L. iners and unclassified Lactobacillus spp was associated with CIN2+ (OR = 3.48; 95% CI, 1.27–9.55). | 45 |
| 2      | 2016 | Seo et al | Patients with CIN (n=65) and control (n=72) | South Korea | L. crispatus and L. iners | 16S rRNA gene sequencing, a food-frequency questionnaire and multivariable logistic regression analysis | CIN | Diet characterized by L. iners-dominant type had a higher risk of CIN, compared with the L. crispatus-dominant type | 46 |
| 3      | 2015 | Mitra et al | Control (n=20), LSL (n=52), HSIL (n=92), and cervical cancer (n=5). | Caucasian, Asian, and Black | L. jensenii | 16S rRNA gene sequencing | LSIL, HSIL, and ICC | Increasing disease severity was associated with decreasing relative abundance of Lactobacillus spp. The vaginal microbiome in HSIL was characterized by lower levels of L. jensenii (P<0.01) compared to LSIL | 47 |
| 4      | 2015 | Oh et al | Women (n=70) and control (n=50) | South Korea | L. iners and L. crispatus | 16S rRNA gene sequencing | CIN | A predominance of L. iners with a concomitant paucity of L. crispatus in the cervical microbiota was associated with CIN risk | 48 |
| 5      | 2015 | Mitra et al | Control (n=20), LSL (n=52), HSIL (n=92), and cancer (n=5). | Caucasian, Asian, and Black | Lactobacillus | 16S rRNA gene sequencing | CIN | Women with CIN have a more diverse Lactobacillus depleted vaginal microbiome, compared to normal women | 49 |
| 6      | 2015 | Kwasniewski Wojciech et al | Women | European | Lactobacillus | 16S rRNA gene sequencing | LSIL and HSIL | Lactobacillus spp are the predominant bacteria in the healthy cervix, HPV negative women but there is low abundance of lactobacillus in women with LSIL, HPV (+) | 50 |
| 7      | 2014 | Silva et al | Patients with evolution (214) and without evolution (n=1970) | Brazilian; Gynecology and Obstetrics Department at a public tertiary-level university hospital between 1995 and 2000 | Lactobacillus sp | Retrospective study and multivariable logistic regression analysis | Intraepithelial lesions; cervical cancer | Lactobacillus sp was risk factor associated with evolution from intraepithelial lesion and invasive neoplasia | 51 |
| 8      | 2014 | Kawana et al | Patients with CIN3 (n=17) | Japanese women; Japan | Lactobacillus casei | ELISPOT assay | CIN | Oral administration of an E7-expressing Lactobacillus-based vaccine can elicit E7-specific mucosal immunity in the cervix of CIN3 patients | 52 |
**Role of Lactobacillus in cervical cancer**

| Year | Authors | Study Design | Participants | Methods | Findings |
|------|---------|--------------|--------------|---------|---------|
| 2013 | Rocha et al | Patients with preneoplastic and neoplastic cervical uterine lesions (n=625) | Public health care services in Divinopolis county, Minas Gerais state, Brazil | Lactobacillus PCR | Lactobacillus sp was the most frequent microorganism (65%) in the patients with preneoplastic and neoplastic cervical uterine lesions |
| 2013 | Dareng et al | Women (n=278) | Nigerian; Abuja, Nigeria | Lactobacillus 16S rDNA gene sequencing, Roche Linear Array(R) HPV genotyping test and logistic regression models | Women with or without HR-HPV infection |
| 2012 | Ou et al | Women were randomized to oral lactobacilli (n=40) and oral placebo (n=40) | Chinese; Taiwan, China | Lactobacilli HPV test, pap smear, and vaginal gram stain; randomized, double-blind, placebo-controlled study | Low relative abundance of Lactobacillus spp is in 50% of HPV infection |
| 1993 | Okawa et al | Patients with stage IIB cervical cancer (n=228) | Spanish; 50 institutions, Spain | Lactobacillus casei Randomized controlled trial | Comparing with women in oral lactobacilli group, women in the placebo group had a significant higher percentage of subsequent CIN lesion during follow-up |
| 1989 | Okawa et al | Patients with stage IIB or III cervical cancer (n=61) | Japanese; Department of Radiology, Tokyo Women's Medical College, Tokyo, Japan | Lactobacillus casei Randomized controlled trial | LC9018 (a biological response modifier prepared from heat-killed Lactobacillus casei YTT9018) could protect the patients from radiation-induced leukopenia during radiotherapy with few side effects |
| 1978 | Mead | Patients with invasive cervical cancer (n=21) | American; Department of Obstetrics and Gynecology at the University of Vermont College of Medicine, Burlington, VT, USA | Lactobacilli Aerobic lactobacilli Bacteria isolation and purification | LC9018 enhanced the therapeutic effect of the irradiation. LC9018 could protect the patients from leukopenia during radiotherapy |

**Notes:** Cervical cancer and precancerous lesions in women were associated with high relative abundance of Lactobacillus and several of its subgenera. Oral lactobacilli (panel number 11) and an E7-expressing Lactobacillus-based vaccine (panel number 8) were able to decrease the risk of CIN. LC9018 protected patients from radiation-induced leukopenia with few side effects.

**Abbreviations:** CCK-8, cell counting kit-8; CIN, cervical intraepithelial neoplasia; CT, community type; HPV, human papillomavirus; HR-HPV, high-risk HPV; HSIL, high-grade squamous intraepithelial lesion; ICC, invasive cervical cancer; L. crispatus, Lactobacillus crispatus; L. iners, Lactobacillus iners; L. jensenii, Lactobacillus jensenii; LSIL, low-grade squamous intraepithelial lesion; PCR, polymerase chain reaction.
**Table 2** Experimental studies of *Lactobacillus* in cervical cancer

| Number | Year | Authors | Experimental animal and cell model | Subgenera of *Lactobacillus* | Methods | Diseases | Findings | Reference |
|--------|------|---------|-----------------------------------|-----------------------------|---------|----------|----------|----------|
| 1      | 2017 | Wang et al | CaSki cells | L. crispatus, L. jensenii, and L. gasseri | MTT assay, flow cytometry, and PCR | Cervical cancer | Supernatants of L. crispatus, L. jensenii, and L. gasseri have inhibitory effects on the viability of cervical cancer cells via regulation of HPV oncogenes and cell cycle-related genes | 43 |
| 2      | 2017 | Li et al | HeLa and U14 cell lines and Xenograft mouse | Lactobacilli | CCK-8, Western blot, and immunohistochemistry | Cervical cancer | Lactobacilli inhibit the migratory ability of cervical cancer cells and the upregulation of E-cadherin may be involved in the molecule mechanism | 58 |
| 3      | 2017 | Sungur et al | Women, cervical cancer cell and Caco-2 cell lines | L. gasseri strains | HPLC, WST-1 cell proliferation assay, ELISA, and PCR | Cervical cancer | EPSs of L. gasseri strains isolated from human vagina induce apoptosis in HeLa cells by associating with an upregulation of Bax and Caspase 3 | 44 |
| 4      | 2017 | Jang et al | Th17 cells and HeLa cell lines | Lactobacillus rhamnosus HN001 (L1) and Lactobacillus acidophilus La-14 (L2) | Enzyme-linked immunosorbent assay, immunoblotting, PCR, and flow cytometry | Cervical cancer | Lactobacillus rhamnosus HN001 (L1) and Lactobacillus acidophilus La-14 (L2) inhibited the adherence of Gardnerella vaginalis to cervical cancer cells | 59 |
| 5      | 2016 | Nouri et al | HeLa cell lines | LRS and LCS | MTT assay and PCR | Cervical cancer | LRS and LCS have antimetastatic and antiproliferative activities on HeLa cell lines | 60 |
| 6      | 2016 | Motevaseli et al | HeLa cells | L. crispatus and Lactobacillus rhamnosus | PCR | Cervical cancer | L. crispatus and Lactobacillus rhamnosus culture supernatants can decrease the expression of ATG14 and BECN1 as well as the HPV E6 oncogene in HeLa cells | 61 |
| 7      | 2015 | Kim et al | CaSki and HeLa cell lines | Lactobacillus casei | Flow cytometry | Cervical cancer | Lactobacillus casei extract cannot inhibit the viability of cervical cancer cells or the growth of cancer cells in the presence of anticancer drugs in vitro | 62 |
| 8      | 2014 | Nami et al | Women; HeLa cell lines and HUVEC normal cells | Lactobacillus plantarum | 16S rDNA gene sequencing, disk diffusion antibiotic susceptibility test, MTT assay, DAPI staining method, and flow cytometry | Cervical cancer | Lactobacillus plantarum SBL, which is isolated from vaginal secretions of adolescent and young adult women, exhibits desirable probiotic properties and remarkable anticancer activity against the HeLa cell lines with no significant cytotoxic effects on HUVEC normal cells | 63 |
| 9      | 2013 | Motevaseli et al | Human normal fibroblast-like cervical (normal cervical) and HeLa (cervical tumor) cells | L. gasseri and L. crispatus | MTT assay, Trypan blue staining, lactate dehydrogenase assay, colorimetric caspase-3 activity assay, and PCR | Cervical cancer | L. gasseri and L. crispatus exert cytotoxic effects on cervical tumor cells and this cytotoxicity is independent of pH and lactate | 64 |
| 10     | 2013 | Ribelles et al | Mice, inbred C57BL | Lactococcus lactis and L. casei | Cell surface display techniques | Cervical cancer | E7-expressing LAB, as a mucosal live vaccine, protects against HPV type 16-induced tumors in mouse | 65 |
| 11     | 2010 | Lee et al | Mice | L. casei | Enzyme-linked immunosorbent assay | Cervical cancer | Oral L. casei bearing the surface-displayed E6 protein induces T-cell-mediated cellular immunity and antitumor effects in mice | 22 |
cells are the promising vaccine against HPV-16 infection. L. casei
HPV-type 16 L1 virus-like particles by recombinant
Western blot, flow
cytometry, and
immunofluorescence
microscopy
Flow cytometry
Flow cytometry
and immunofluorescence
microscopy
Cervical
cancer
Cervical
cancer
Cervical
cancer
Isolation of
Lactobacillus sp (P<0.05) is associated with low-grade CIN or normal histology

Notes: Cancer cell and animal models and molecular biology techniques were used to study the role of Lactobacillus and several of its subgenera in cervical cancer. Lactobacillus, several subgenera, and their supernatants had antimetastatic and antiproliferative effects in cervical cancer cell lines by regulating cancer-related genes and eliciting an immunological response.

Abbreviations: DAPI, 4′,6-diamidino-2-phenylindole; ELISA, enzyme-linked immunosorbent assay; EPSs, exopolysaccharides; HPV, human papillomavirus; L. casei, Lactobacillus casei; L. crispatus, Lactobacillus crispatus; L. gasseri, Lactobacillus gasseri; L. jensenii, Lactobacillus jensenii; LAB, lactic acid bacteria; LCS, L. crispatus supernatant; LRS, Lactobacillus rhamnosus supernatant.

L. casei-PgsA-E7 (HPV-type 16 E7 protein displayed on lactobacillus) can improve T cells with specific mucosal E7-type1 immune responses and induce mucosal cytotoxic cellular immune responses.

Oral administration of L. casei-PgsA-E7 (HPV-type 16 E7 protein displayed on lactobacillus) induces E7-specific antitumor effects in C57BL6 mice.

HPV-type 16 L1 virus-like particles by recombinant L. casei cells are the promising vaccine against HPV-16 infection.

Isolation of Lactobacillus sp (P<0.05) is associated with low-grade CIN or normal histology.

In addition to cervical cancer, Lactobacillus is associated with the proliferation and regulation of cells of other cancer types, such as breast cancer, colorectal cancer, gastric cancer, and oral cancer. Observations in these other cancers may offer insights into the study of Lactobacillus in cervical cancer. The main observations regarding Lactobacillus in cervical cancer are as follows: (1) Lactobacillus can activate the innate immune response by binding to a specific receptor that exists on the surface of human cells; (2) Lactobacillus can activate the innate immune response and secretion factors produced by immune cells, such as dendritic cells (DCs), macrophages and immunological dendritic cells (IDCs); (3) natural killer (NK) cells, as thymus-derived cells, have unique advantages; (4) large amounts of cytokines and other factors produced by Lactobacillus play a role in the proliferation and regulation of cells of other cancer types.

In addition to cervical cancer, Lactobacillus is associated with the proliferation and regulation of cells of other cancer types. Some experimental studies found that Lactobacillus and its metabolites, which are used as treatment agents, have unique advantages.

12 2010 Adachi et al
C57BL/6 mice L. casei Flow cytometry Cervical cancer L. casei-PgsA-E7 (HPV-type 16 E7 protein displayed on lactobacillus) can improve T cells with specific mucosal E7-type1 immune responses and induce mucosal cytotoxic cellular immune responses.

13 2006 Poo et al
Mice L. casei Western blot, flow
cytometry, and
immunofluorescence
microscopy Western blot, flow
cytometry, and
immunofluorescence
microscopy Cervical cancer Cervical cancer

14 2006 Aires et al
Mice L. casei Western blotting, electron
microscopy analysis, immunofluorescence, immunosorbent assay, and enzyme-linked immunosorbent assay Isolation of Lactobacillus sp (P<0.05) is associated with low-grade CIN or normal histology

15 1999 McNicol et al
CaSki carcinoma cell line Lactobacillus acidophilus PCR and quantitative culture CIN; HPV 16 infection Isolation of Lactobacillus sp (P<0.05) is associated with low-grade CIN or normal histology.
and 4) *Lactobacillus* can selectively locate to solid cancers and can be used as a vector for gene therapy and targeted therapies.35

The diagnosis and treatment of cervical cancer have been advanced considerably in recent years, but there is still a long way to go in regard to cancer prevention. This review cannot include some unpublished research or ongoing studies. There is also a lack of large-scale multicenter clinical trials and clinical prospective cohort studies in the literature. A perfect theory cannot be constructed for the mechanism of action of *Lactobacillus* in cervical cancer. Vaginal *Lactobacillus* and its metabolites may provide a novel insight into the prevention of cervical cancer. Thus, we put forth some future directions for further study.

**Future directions**

**Elucidate the role of vaginal *Lactobacillus* in cervical cancer**

*Lactobacillus* is the dominant bacteria in the vagina and affects the growth of other bacteria.32 There appears to be a complex relationship between cervical cancer and vaginal *Lactobacillus*. However, many problems deserve further consideration. How do the community structure and diversity of *Lactobacillus* vary with differences in race, region, lifestyle, and diet? How does *Lactobacillus* drive the occurrence and development of cervical cancer? What is the role of *Lactobacillus* metabolites in balancing vaginal microecology and the development of cervical cancer?

---

**Figure 2** Network illustrating the effects of *Lactobacillus* in cervical cancer.

**Note:** An association network for *Lactobacillus* in cervical cancer was constructed based on the analysis of experimental studies and allows improved visualization of these studies.

**Abbreviations:** HPV, human papillomavirus; *L. acidophilus*, *Lactobacillus acidophilus*; *L. casei*, *Lactobacillus casei*; *L. crispatus*, *Lactobacillus crispatus*; *L. gasseri*, *Lactobacillus gasseri*; *L. jensenii*, *Lactobacillus jensenii*; *L. lactis*, *Lactobacillus lactis*; *L. plantarum*, *Lactobacillus plantarum*; *L. rhamnosus*, *Lactobacillus rhamnosus*.
Elucidate the immunological functions mediated by vaginal *Lactobacillus* in cervical cancer

Immunotherapy provides a broad perspective for the treatment of cancers. Vaginal *Lactobacillus* and its metabolites do affect the immune system in cervical cancer. Though much effort has been made into understanding the mechanisms of this effect, many bottlenecks must be addressed before stepping from the imbalanced vaginal microecological mechanisms of this effect, many bottlenecks must be addressed before stepping from the imbalanced vaginal microecological system to cervical cancer genesis and development. *Lactobacillus* is an easily available probiotic that is safe and has no side effects or toxicity. The envelope of *Lactobacillus* is often used as a carrier to express an alternative antigen for vaccines, which may provide a novel idea for the primary prevention of cervical cancer. A cervical cancer vaccine based on *Lactobacillus* with an HPV vaccine promises to be a new method for the prevention of cervical cancer. Prospective studies on cervical cancer incidence after intervention with the *Lactobacillus* vaccine should be performed.

Elucidate the molecular mechanism by which *Lactobacillus* inhibits cervical cancer

*Lactobacillus* inhibits the proliferation of cells from multiple cancer types. Most studies have focused on the relationship between *Lactobacillus* and cancer, but the mechanisms underlying this relationship have yet to be clarified. Many enzymes and peptides and the lactic acid secreted by *Lactobacillus* are involved in activating and regulating important signaling molecules and pathways in cervical cancer. It is necessary to elucidate the specific molecular mechanism or construct the molecular regulatory network in future research. *Lactobacillus* acts as a valuable cloning vector and is currently mainly used as a plasmid vector for the experimental research of cancer in vitro. This use may suggest additional therapeutic use as a carrier to express anticancerous or encapsulated anticarcinogens in the future.

In light of the importance of *Lactobacillus* in cervical cancer, much attention has been paid to the study of vaginal microecology in recent years. *Lactobacillus* has shown tremendous promise for the prevention and treatment of cervical cancer. However, knowledge of vaginal microecology and *Lactobacillus* is far from complete. More research will be required before clinical application of *Lactobacillus* in cervical cancer is achieved.

**Acknowledgment**

This work was supported by the Huzhou Public Welfare Technology Application Research Program (2016GYSB14).

**Disclosure**

The authors report no conflicts of interest in this work.

**References**

1. Li L, Wang X. MicroRNA-296 targets specificity protein 1 to suppress cell proliferation and invasion in cervical cancer. *Oncol Res*. Epub 2017 Dec 14.
2. Yang PM, Chou CJ, Tseng SH, Hung CF. Bioinformatics and in vitro experimental analyses identify the selective therapeutic potential of interferon gamma and apigenin against cervical squamous cell carcinoma and adenocarcinoma. *Oncotarget*. 2017;8(28):46145–46162.
3. Musa J, Achenbach CJ, O’Dwyer LC, et al. Effect of cervical cancer education and provider recommendation for screening on screening rates: a systematic review and meta-analysis. *PLoS One*. 2012;7(9):e0183924.
4. Yang J, Nolte FS, Chajewski OS, et al. Cytology and high risk HPV testing in cervical cancer screening program: outcome of 3-year follow-up in an academic institute. *Diagn Cytopathol*. 2017;46(1):22–27.
5. Chase D, Goulder A, Zenhausan F, Monk B, Herbst-Kralovetz M. The vaginal and gastrointestinal microbiomes in gynecologic cancers: a review of applications in etiology, symptoms and treatment. *Gynecol Oncol*. 2015;138(1):190–200.
6. Hillemanns P, Soergel P, Hertel H, Jentschke M. Epidemiology and early detection of cervical cancer. *Oncol Res Treat*. 2016;39(9):501–506.
7. Yue XA, Chen P, Tang Y, Wu X, Hu Z. The dynamic changes of vaginal microbiome in first trimester pregnant women influences of reproductive age. *J Clin Microbiol*. 2017;55:140.
8. Niu XX, Li T, Zhang X, Wang SX, Liu ZH. Encapsulated anticarcinogens in the future. *Oncotarget*. 2016;7(47):77393–77403.
9. Smith WL, Hedges SR, Mordechai E, et al. Cervical and vaginal flora associated organisms and commensal *Lactobacillus* species in women with an HPV vaccine based on *Lactobacillus* iners, the unusual suspect. *J Clin Microbiol* (Engl). 2017;130(3):273–279.
10. Vanechoutte M. *Lactobacillus iners*, the unusual suspect. *Res Microbiol*. 2017;168(9):826–836.
11. Nasioudis D, Forney LJ, Schneider GM, et al. The composition of the vaginal microbiome in first trimester pregnant women influences the level of autophagy and stress in vaginal epithelial cells. *J Reprod Immunol*. 2017;123:35–39.
31. Champe M, Wong AM, Champe J, et al. The role of the vagi -

30. Collins SL, McMillan AM, Seney S, et al. Evaluation of lactitol,

27. Overman BA. The vagina as an ecologic system. Current understanding

26. Wilting SM, Steenbergen RDM. Molecular events leading to HPV -

36. Cheng Z, Xu H, Wang X, Liu Z. -dominated vaginal microbiota establishes a promising prebiotic can-

32. Marschalek J, Farr A, Marschalek ML, et al. Influence of orally

21–28. women with cervical abnormalities and cancer. 2016;52:

21. Wang S, Wang Q, Yang E, Yang L, Li T, Zhuang H. Antimicrobial

19. Zadravec P, Štrukelj B, Berlec A. Improvement of LysM-mediated

18. Sgibnev AV, Kremleva EA. Vaginal protection by H2O2-producing

37. Klimek R, Klimek M, Jasiczek D. Immunotherapy of cervical

35. Mohamadzadeh M, Kläenhammer TR. Specific Lactobacillus species
differentially activate toll-like receptors and downstream signals in

dendritic cells. Expert Rev Vaccines. 2008;7(8):1155–1164.

34. Takeda K, Okumura K. Effects of a fermented milk drink containing

Lactobacillus casei strain Shiratai on the human NK-cell activity. J Nutr.

2007;137(2):791S–793S.

33. Kitazawa H, Watanabe H, Shimosato T, Kawai Y, Itoh T, Saito T. Immunosstimulatory oligonucleotide, CpG-like motif exists in Lacto-

baccillus delbrueckii ssp. bulgaricus NIAI B6. Int J Food Microbiol.

1993;85(3):11–21.

32. Esfandiary A, Taheri-Esfahani Z, Abedin-Do A, et al. Lactobacilli modulate hypoxia-inducible factor (HIF)-1 regulatory pathway in triple

negative breast cancer cell line. Cell J. 2016;18(2):237–244.

31. Kovachev S. Defence factors of vaginal lactobacilli. Crit Rev Microbiol.

2017;44(1):31–39.

30. Wang KD, Xu DJ, Wang BY, Yan DH, Lv Z, Su JR. Inhibitory effect of

vaginal Lactobacillus supernatants on cervical cancer cells. Probiotics

Antimicrob Proteins. Epub 2017 Oct 25(suppl 1):1–7.

29. Sungur T, Ashlin B, Karaaslan C, Aktas B. Impact of exopolysaccharides (EPSs) of Lactobacillus gasseri strains isolated from human vagina on cervical tumor cells (HeLa). Anaerobe. 2017;47:137–144.

28. Piaytlahike CJ, Ollberding NJ, Kumar R, Malacuso M, Alvarez RD, Morrow CD. Cervical microbiota associated with higher grade cervi-
cal intraepithelial neoplasia in women infected with high-risk human

papillomaviruses. Cancer Prev Res (Phila). 2016;9(5):357–366.

27. Seo SS, Oh HY, Lee JK, Kong JS, Lee DO, Kim MK. Combined effect

of diet and cervical microbiome on the risk of cervical intraepithelial

neoplasia. Clin Nutr. 2016;35(6):1434–1441.

26. Mitra A, MacIntyre DA, Lee YS, et al. Cervical intraepithelial neoplasia
disease progression is associated with increased vaginal microbiome

diversity. Sci Rep. 2015;5:16865.

25. Oh HY, Kim BS, Seo SS, et al. The association of uterine cervical

microbiota with an increased risk for cervical intraepithelial neoplasia

in Korea. Clin Microbiol Infect. 2015;21(7):674.e1–e9.

24. Mitra A, MacIntyre DA, Lee YS, et al. The vaginal microbiome of

women with cervical intraepithelial neoplasia. Microbiome. 2015;29(25):976–977.

23. Wojciech K, Kotarski J, Barczynski B, et al. A meta genomic approach
to characterization of the cervix microbiome during HPV dependent
carcinogenesis. Int J Gynecol Cancer. 2015;9(25):848.

22. Silva C, Almeida EC, Côbo Ede C, Zepferino VF, Murta EF, Etchebehere RM. A retrospective study on cervical intraepithelial lesions of low-
grade and undetermined significance: evolution, associated factors and
cytostatological correlation. Sao Paulo Med J. 2014;132(2):92–96.

21. Kawana K, Adachi K, Kojima S, et al. Oral vaccination against HPV

E7 for treatment of cervical intraepithelial neoplasia grade 3 (CIN3)
elicits E7-specific mucosal immunity in the cervix of CIN3 patients.

Vaccine. 2014;32(47):6233–6239.

20. Rocha VR, Schlüffner Rde O, Soares II, et al. Cervical uterine lesions:
an epidemiological and molecular investigation in Midwestern Minas

Gerais, Brazil. J Med Virol. 2013;85(5):860–865.

19. Darend EO, Ma B, Famoo AO, et al. Prevalent high-risk HPV infec-
tion and vaginal microbiota in Nigerian women. Epidemiol Infect.

2016;144(1):123–137.

18. Ou YC, Lin H Randomized, double-blind, placebo-controlled study

of oral lactobacilli to facilitate the clearance of genital high risk HPV

infection in women. Int J Gynecol Cancer. 2012;14(12):E695.

17. Okawa T, Niibe H, Arai T, et al. Effect of LC9018 combined with radia-
tion therapy on carcinoma of the uterine cervix. A phase III, multicenter,

randomized, controlled study. Cancer. 1993;72(6):1949–1954.

16. Okawa T, Kita M, Arai T, et al. Phase II randomized clinical trial of

LC9018 concurrently used with radiation in the treatment of carcinoma of

the uterine cervix. Its effect on tumor reduction and histology. Cancer.

1989;64(9):1769–1776.
58. Li X, Wang H, Du X, et al. Lactobacilli inhibit cervical cancer cell migration in vitro and reduce tumor burden in vivo through upregulation of E-cadherin. Oncol Rep. 2017;38(3):1561–1568.

59. Jang SE, Jeong JJ, Choi SY, Kim H, Han MJ, Kim DH. Lactobacillus rhamnosus HN001 and Lactobacillus acidophilus La-14 attenuate Gardnerella vaginalis-infected bacterial vaginosis in mice. Nutrients. 2017;9(6):E531.

60. Nouri Z, Karami F, Neyazi N, et al. Dual anti-metastatic and anti-proliferative activity assessment of two probiotics on HeLa and HT-29 cell lines. Cell J. 2016;18(2):127–134.

61. Motevaseli E, Azam R, Akrami SM, et al. The effect of Lactobacillus crispatus and Lactobacillus rhamnosus culture supernatants on expression of autophagy genes and HPV E6 and E7 oncoproteins in the HeLa cell line. Cell J. 2016;17(4):601–607.

62. Kim SN, Lee WM, Park KS, Kim JB, Han DJ, Bae J. The effect of Lactobacillus casei extract on cervical cancer cell lines. Contemp Oncol (Pozn). 2015;19(4):306–312.

63. Nami Y, Abdullah N, Haghshenas B, Radiah D, Rosli R, Khosroushahi AY. Assessment of probiotic potential and anticancer activity of newly isolated vaginal bacterium Lactobacillus plantarum SBL. Microbiol Immunol. 2014;58(9):492–502.

64. Motevaseli E, Shirzad M, Akrami SM, Mousavi AS, Mirsalehian A, Modarressi MH. Normal and tumour cervical cells respond differently to vaginal lactobacilli, independent of pH and lactate. J Med Microbiol. 2013;62(pt 7):1065–1072.

65. Ribelles P, Benbouziane B, Langella P, Suárez JE, Bermúdez-Humarán LG. Protection against human papillomavirus type 16-induced tumors in mice using non-genetically modified lactic acid bacteria displaying E7 antigen at its surface. Appl Microbiol Biotechnol. 2013;97(3):1231–1239.

66. Adachi K, Kawana K, Yokoyama T, et al. Oral immunization with a Lactobacillus casei vaccine expressing human papillomavirus (HPV) type 16 E7 is an effective strategy to induce mucosal cytotoxic lymphocytes against HPV16 E7. Vaccine. 2010;28(16):2810–2817.

67. Poo H, Pyo HM, Lee TY, et al. Oral administration of human papillomavirus type 16 E7 displayed on Lactobacillus casei induces E7-specific anti-tumor effects in C57/BL6 mice. Int J Cancer. 2006;119(7):1702–1709.

68. Aires KA, Cianciarullo AM, Carneiro SM, et al. Production of human papillomavirus type 16 L1 virus-like particles by recombinant Lactobacillus casei cells. Appl Environ Microbiol. 2006;72(1):745–752.

69. McNicol PJ, Parasevas M, Guijon FB. The effect of vaginal microbes on in vivo and in vitro expression of human papillomavirus 16 E6-E7 genes. Cancer Detect Prev. 1999;23(1):13–21.